TOVX - Theriva Biologics, Inc.
Close
1.585
-0.045 -2.839%
Share volume: 7,253
Last Updated: Thu 26 Dec 2024 08:30:13 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.63
-0.05
-2.76%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
35.38%
1 Month
37.50%
3 Months
-13.73%
6 Months
633.33%
1 Year
308.54%
2 Year
318.95%
Key data
Stock price
$1.58
DAY RANGE
$1.41 - $1.64
52 WEEK RANGE
$0.14 - $7.15
52 WEEK CHANGE
$298.28
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Steven A. Shallcross
Region: US
Website: therivabio.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: therivabio.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Synthetic Biologics, Inc. develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade intravenous beta-lactam antibiotics in gastrointestinal (GI) tract. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.
Recent news